Gland Pharma Q2 FY26 Earnings Results

Gland Pharma, a Hyderabad-based global injectable-focused pharma company, reported steady financial growth in Q2 FY26 with strong performance in key international markets.

Financial Highlights:

• Revenues increased 5.76% year on year to ₹1,487 crore from ₹1,406 crore.
• Total expenses rose 6.45% to ₹1,287 crore from ₹1,209 crore.
• Consolidated net profit rose 12.2% to ₹184 crore from ₹164 crore.
• Earnings per share (EPS) improved 12.29% to ₹11.15 from ₹9.93.

Key Business Drivers:

• Core business excluding European subsidiary Cenexi grew 7% in PAT with EBITDA margins steady at 35%.
• Cenexi, affected by a planned shutdown, recorded 21% revenue growth to ₹410 crore with infrastructure upgrades completed.
• Strong momentum expected in second half driven by new product launches and Cenexi’s recovery.
• US business grew 10% YoY and Europe 16% YoY, supported by accelerated topline growth in Cenexi.
• Research & Development investments increased, with seven new US molecule launches and multiple ANDA filings and approvals.

Outlook:

Management is confident about mid-teen revenue growth in FY27 supported by pipeline advancements, capacity expansion, and sustained growth across geographies. Planned capacity additions in biologics and other high-end modalities aim to strengthen future prospects.

Gland Pharma’s Q2 FY26 results reflect robust execution, margin expansion, and strategic positioning for long-term value creation.

Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.